BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · IEX Real-Time Price · USD
18.87
-0.45 (-2.33%)
At close:
May 26, 2023, 4:00 PM
19.30
+0.43 (2.28%)
After-hours:
May 26, 2023, 6:46 PM EDT
BioXcel Therapeutics Market Cap
BioXcel Therapeutics has a market cap or net worth of $550.24 million as of May 30, 2023. Its market cap has increased by 48.51% in one year.
Market Cap
550.24M
Enterprise Value
480.49M
1-Year Change
48.51%
Ranking
Category
Stock Price
$18.87
Market Cap Chart
Since March 8, 2018, BioXcel Therapeutics's market cap has increased from $167.60M to $550.24M, an increase of 228.31%. That is a compound annual growth rate of 25.58%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 26, 2023 | 550.20M | -2.34% |
| May 25, 2023 | 563.40M | -25.49% |
| May 24, 2023 | 756.10M | 0.35% |
| May 23, 2023 | 753.50M | -0.30% |
| May 22, 2023 | 755.80M | 2.77% |
| May 19, 2023 | 735.40M | -4.94% |
| May 18, 2023 | 773.60M | -1.23% |
| May 17, 2023 | 783.20M | -2.48% |
| May 16, 2023 | 803.10M | 1.15% |
| May 15, 2023 | 794.00M | -0.87% |
| May 12, 2023 | 801.00M | 1.47% |
| May 11, 2023 | 789.40M | -5.28% |
| May 10, 2023 | 833.40M | 4.84% |
| May 9, 2023 | 794.90M | 4.07% |
| May 8, 2023 | 763.80M | 13.63% |
| May 5, 2023 | 672.20M | 2.13% |
| May 4, 2023 | 658.20M | 1.61% |
| May 3, 2023 | 647.80M | 7.41% |
| May 2, 2023 | 603.10M | -0.10% |
| May 1, 2023 | 603.70M | 0.92% |
| Apr 28, 2023 | 598.20M | 0.05% |
| Apr 27, 2023 | 597.90M | -1.61% |
| Apr 26, 2023 | 607.70M | -0.25% |
| Apr 25, 2023 | 609.20M | -8.34% |
| Apr 24, 2023 | 664.60M | 3.38% |
View and export this data all the way back to 2018.
Start Free Trial.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| HilleVax, Inc. | 660.13M |
| OraSure Technologies, Inc. | 357.52M |
| ALX Oncology Holdings Inc. | 278.32M |
| EyePoint Pharmaceuticals, Inc. | 203.41M |
| Fulcrum Therapeutics, Inc. | 179.72M |
| Absci Corporation | 158.18M |
| Heron Therapeutics, Inc. | 153.24M |
| C4 Therapeutics, Inc. | 151.12M |
| Athira Pharma, Inc. | 99.81M |
| Enochian Biosciences, Inc. | 54.79M |